Healthcare / BiotechnologyKOSDAQ
$12120.00
-480.00 (-3.81%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-12.9B · quality 66.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$297.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-7.8%
↓Gross Margin
19.0%
↓Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-49.9%
FCF CAGR
—
FCF margin
-344.1%
FCF / Net income
1.44x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.76B · net income $-8.99B · FCF $-12.94B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.76B | $3.76B | $2.36B | $3.42B | $29.87B |
| Net Income | $-8.99B | $-8.99B | $-10.24B | $-8.76B | $-6.63B |
| EBITDA | $-7.71B | $-7.71B | $-8.91B | $-6.27B | $3.02B |
| EPS | -374.00 | -374.00 | -429.00 | -449.00 | -316.00 |
| Gross Margin | 19.0% | 19.0% | -30.8% | -7.9% | 83.7% |
| Operating Margin | -300.5% | -300.5% | -648.2% | -506.2% | 8.1% |
| Net Margin | -239.0% | -239.0% | -433.6% | -256.2% | -22.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.01 | 0.27 |
| Current Ratio | 126.75 | 126.75 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-12.94B | $-12.94B | $-16.19B | $-11.17B | $2.46B |
| Returns | |||||
| ROE | -7.8% | -7.8% | -8.3% | -7.0% | -6.2% |
| Valuation | |||||
| EV/EBITDA | — | — | — | — | 48.99 |
| P/B | 2.53 | 2.53 | 4.16 | 3.49 | 1.74 |
| Growth & Yield | |||||
| Revenue Growth | 59.2% | 59.2% | -30.9% | -88.6% | — |
| EPS Growth | 12.8% | 12.8% | 4.5% | -42.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-429.00 → -374.00
Residual
-7.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.